Showing results (1651-1660 of 1,761) with videos related to

Sort By:
Pageof 177
Blood|February 18, 2010
Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique studyEtienne Coyaud, Stephanie Struski, Nais Prade, et al.
Advances in Radiation Oncology|December 4, 2023
The Pediatric Proton and Photon Therapy Comparison Cohort: Study Design for a Multicenter Retrospective Cohort to Investigate Subsequent Cancers After Pediatric Radiation TherapyAmy Berrington de González, Todd M Gibson, Choonsik Lee, et al.
Circulation|April 15, 2016
Analysis of Workflow and Time to Treatment on Thrombectomy Outcome in the Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) Randomized, Controlled TrialBijoy K Menon, Tolulope T Sajobi, Yukun Zhang, et al.
Journal of Medicinal Chemistry|March 14, 2022
Targeting the Mitotic Kinesin KIF18A in Chromosomally Unstable Cancers: Hit Optimization Toward an In Vivo Chemical ProbeNuria A Tamayo, Matthew P Bourbeau, Jennifer R Allen, et al.
Journal of Stroke|February 7, 2025
Factors Influencing Nerinetide Effect on Clinical Outcome in Patients Without Alteplase Treatment in the ESCAPE-NA1 TrialMayank Goyal, Bijoy K Menon, Johanna Ospel, et al.
Stroke|December 15, 2020
Thrombus Migration and Fragmentation After Intravenous Alteplase Treatment: The INTERRSeCT StudyTomoyuki Ohara, Bijoy K Menon, Fahad S Al-Ajlan, et al.
International Journal of Cancer|August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18A Szarewski, W A J Poppe, S R Skinner, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Gynecologic Oncology|September 4, 2012
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trialEdith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
Pageof 177